Seeking Help From Fruta Planta

By Author: long jing
Total Articles: 297
Comment this article

To solve the problem of obesity, people need effective fruta planta pills. But the drugs business in mainland China, the relatively slow growth in urgent need of a new growth point. 1.2 Chemical name: "Introduction (Reductil) sibutramine hydrochloride, Abbott pharmaceutical R & D by German Keno (Knoll).

After the United States acquired the promotion of the products in the world was a great success in Europe 3 U.S. market accounted for 30% to 50% of the market share of the weight loss drugs, 50% market share in Hong Kong, Taiwan 70 percent in China in 2001, but suffered a crisis in Italy recall events, as well as domestic generic violations such as mass advertising of the drug manufacturers a series of the Gui adverse events have had to stop selling the drug business in urgent need of a new growth point, the company decided, such as some areas in mainland China in 2007. fruta planta reduce weight is becoming a serious health problem.

In Shanghai, Jiangsu, Zhejiang and other places ...
... the re-launch the product, whether to proceed with a national promotion and the sales situation, the original intention of this project. 1.3 the concept of obesity and its hazards of obesity is a chronic disease of the excessive accumulation of fat in a physical as well as a threat to health, the World Health Organization (WHO ) was officially announced that obesity is a disease of high prevalence of obesity in the United States, and rising over the past 10 years, the total incidence rate increased from 25% to 33%, an increase of 1/3 in 1999. It engenders a great potential fruta planta treatment market.   The rapid development society boost the needs for successfulfruta planta.   And provide services customers in over 130 countries in the world, with more than 60,000 employees in over 100 regional engaged in the manufacture, distribution, research and development and other services. In 2006, the U.S. Abbott reported sales and profit from continuous operations were $ 22.9 billion and $ 3.4 billion. U.S. Abbott also reported on the 328th consecutive quarterly dividend paid to shareholders since 1924. In addition, Abbott dividends have been increased to 33 years in 2005. Its medical products business generated sales of more than $ 8 billion business including diagnostics, nutrition, diabetes care, molecular.

 Chinese economic and great improvement in the standard of living lead to many people who have obese problems, so they are seeking help from fruta planta. Take care of the point, vascular, spine and animal health. Its pharmaceutical business generated sales of more than $ 13 billion business, including pharmaceutical factories in the U.S. and abroad. U.S. Abbott has a leading position in the multiple billions of dollars in business, get a unique income and the balance of growth opportunities and cash flow sources, enabling the company to be able to invest in the future. 2005 To further enhance the vitality of enterprises, the continued success of the U.S. Abbott invested over 1.8 billion U.S. dollars in research and development.

In 2005, U.S. Abbott obtained from the continuous operation of operating cash flow of $ 5.0 billion. Abbott has four offices in China, a joint venture factory and a trading company. Its nutrition business with 2006 sales of over one billion yuan, especially the reputation of its infant formula in the high-end market.